Article Sidebar
Views pdf: 117
ESTIMATION OF LIVER FIBROSIS BY FIBROSCAN IN PATIENTS WITH NON-ALCOHOL FATTY LIVER DISEASE AT THE GASTROINTESTINAL-HEPATOLOGY CENTER, BACH MAI HOSPITAL IN 2024
Main Article Content
Abstract
Objective: To evaluate the results of Fibrosan in patients with non-alcoholic fatty liver disease. Subjects and methods: Including 152 patients with non-alcoholic fatty liver disease who came for examination and treatment at the Department of Examination and Treatment on Demand, Bach Mai Hospital from March 2024 to June 2024. Results: The average age in our study was 48.2 ± 15.4. The ratio of female patients was higher than that of male patients, female/male = 1.4. The majority of patients were overweight, obese (63.1%) and physically inactive (79.6%). The mean values of cholesterol, triglyceride, AST, ALT, GGT were 5.3 ± 1.4 mmol/l; 2.14 ± 1.67 mmol/l; 35.8 ± 28.5 U/L; 55.4 ± 58.1U/L; 53.4 ± 46.9 U/L, in which increased triglycerides were the most common, accounting for 65.5%, ALT increased higher than AST (40.8% more than 23.7%). Average elasticity was 5.9 ± 3.1 kPa, most patients had mild fibrosis, accounting for 78.3%; the rate of patients with significant fibrosis F2, F3, F4 was 9.9%; 9.2%; 2.6%, respectively. The rate of patients with significant fibrosis in the BMI ≥ 25 kg/m2 group was 33.3%, higher than the group with BMI < 25 kg/m2 at 12.8%, the difference was statistically significant with p=0.002. The rate of significant fibrosis in the diabetic group was 32.1%, higher than that in the non-diabetic group at 16.2%, the difference was statistically significant with p<0.05. There was no difference in the degree of fibrosis between age groups, gender, smoking history, history of hypertension, history of dyslipidemia. Conclusion: Patients with non-alcoholic fatty liver disease (NAFLD) had liver elasticity mainly in the mild fibrosis group F0-F1 (78.3%); only 4 patients had cirrhosis (2.6%). The rate of patients with significant fibrosis was higher in the group with BMI ≥ 25 kg/m2 and a history of diabetes, the difference was statistically significant, p<0.05.
Article Details
Keywords
non-alcoholic fatty liver disease, degree of fibrosis, related factors.
References
1. Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023; 79(3): 842-852. doi:10.1016/j.jhep. 2023.04.036.
2. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22(6): 778-787. doi:10.1111/ j.1440-1746.2007.05001.x.
3. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40(5): 371-378. doi:10.1016/j.dld. 2007.10.019.
4. Đỗ Văn Tá. Nghiên cứu mối liên quan giữa lâm sàng, cận lâm sàng với chỉ số fibrsocan trong chẩn đoán xơ hóa gan ở bệnh nhân đến khám và điều trị tại Bệnh viện 199. Tạp chí Y học Việt Nam. 2024;538(1): 227-231. doi:10.51298/ vmj.v538i1.9360.
5. Nguyễn Xuân Khái, Phạm Văn Việt, Hoàng Đình Anh. Nghiên cứu mối liên quan của thông số gan nhiễm mỡ trên fibroscan với các đặc điểm nhân trắc học, đường máu và mỡ máu ở bệnh nhân đái tháo đường típ 2. Tạp chí Y học Việt Nam. 2024; 539(2): 55-58. doi:10.51298/ vmj.v539i2.9794.
6. Al Danaf L, Hussein Kamareddine M, Fayad E, Hussain A, Farhat S. Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis. World J Hepatol. 2022;14(4): 744-753. doi:10.4254/ wjh.v14.i4.744.
7. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-462. doi:10. 1002/hep.23312.
8. Stepanova M, Aquino R, Alsheddi A, Gupta R, Fang Y, Younossi Z. Clinical predictors of fibrosis in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics. 2010;31(10): 1085-1094. doi:10.1111/j.1365-2036.2010.04266.x.
9. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(11):1224-1229, 1229.e1221-1222. doi:10.1016/j.cgh.2009.06.007.